

Supplementary table

Clinical	N=28	Hospital Code Group			
		Bronchiolitis	OALRI	Wheeze	Other
Bronchiolitis	2	-	2	-	-
OALRI	9	3	-	6	-
WRS	10	-	9	-	1
Other	7	2	5	-	-

Supplementary table 1: Clinician re-coding of hospital admissions

OALRI, other acute lower respiratory tract infection; WRS, wheeze responsive to salbutamol.

Bronchiolitis				
Year		2019	2020	
Total		271	181	p-value
Median age in months (IQR)		3 (1.4-6.9)	3.7 (1.6-8.8)	0.1
WA Metropolitan region	N (% total)	225 (83)	157 (86.7)	0.29
		N	202	138
Under 12 months	Rate per 1000	8	5.47	< 0.001
		95% CI	6.9- 9.2	4.6- 6.5
Demographics		N (% total)	N (% total)	p-value
Male		155 (57.2)	96 (53)	0.38
Aboriginal and Torres Strait Islander		26 (9.6)	15 (8.3)	0.64
Lowest quintile of IRSAD		28 (10.3)	14 (7.7)	0.35
Pre-existing condition		N (% total)	N (% total)	p-value
Preterm (<37 weeks)		67 (24.7)	17 (9.4)	< 0.001
Neurological/ syndrome		5 (1.8)	6 (3.3)	0.31
sCHD		7 (2.6)	5 (2.8)	0.9
Immunocompromised		1 (0.4)	1 (0.6)	0.76
Clinical findings		N (% total)	N (% total)	p-value
Fever		151 (55.7)	112 (61.9)	0.19
Subcostal recessions		182 (67.2)	103 (56.9)	0.03
Wheeze		127 (46.9)	88 (48.6)	0.72
Respiratory support at admission		N (% total)	N (% total)	p-value
Any respiratory support		137 (50.6)	101 (55.8)	0.28
Low flow oxygen		75 (27.7)	75 (41.4)	0.003
Pressure support		58 (21.4)	25 (13.8)	0.04
Mechanical		4 (1.5)	1 (0.6)	0.38
Peak Respiratory Support		N (% total)	N (% total)	p-value
Any respiratory support		197 (72.7)	140 (77.3)	0.27
Low flow oxygen		105 (38.7)	89 (49.2)	0.03

Pressure support	88 (32.5)	50 (27.6)	0.27
Mechanical	4 (1.5)	1 (0.6)	0.38
ICU admission	31 (11.4)	15 (8.3)	0.29
Antibiotics	N (% total)	N (% total)	p-value
During admission	72 (26.6)	39 (21.5)	0.22
Indication: Bacterial ALRI	36 (13.3)	16 (8.8)	0.14
On discharge	22 (8.1)	12 (6.6)	0.55
Clinical Intervention	N (% total)	N (% total)	p-value
Blood tests	140 (51.7)	70 (38.7)	0.01
CXR	80 (29.5)	43 (23.8)	0.18
Length of Stay	Days (IQR)	Days (IQR)	p-value
ALL	2.7 (1.5-4)	2.1 (1.2-3.7)	0.04
Excluding <37wk	2.4 (1.4-3.7)	1.93 (1.1-3.5)	0.39
Re-admitted 7 days	8 (3)	12 (6.6)	0.07

Supplementary Table 2: Comparison of demographic and clinical features of RSV bronchiolitis admissions in 2019 and 2020.

CI, confidence interval; CXR, chest X-ray; ICU, intensive care unit; IQR, interquartile range; IRSAD, Index of Relative Socio-economic Advantage and Disadvantage; N, number; RSV, respiratory syncytial virus; sCHD, significant congenital heart disease;

OALRI				
Year		2019	2020	
Total		113	145	p-value
Median age in months		22.9	21.6	0.5
(IQR)		(17.1-34.5)	(17-29.3)	
WA Metropolitan Region	N (% total)	90 (79.6)	133 (91.7)	0.01
Between 12-24 months				
	N	41	78	
	Rate per 1000	1.6	3.1	<0.001
	95% CI	1.14 -2.15	2.44 -3.86	
Between 24-48 months				
	N	28	44	
	Rate per 1000	0.52	0.84	0.06
	95% CI	0.35-0.75	0.61-1.12	
Demographics		N (% total)	N (% total)	p-value
	Male	72 (63.7)	74 (51)	0.04
	Aboriginal and Torres Strait Islander	11 (9.7)	8 (5.5)	0.2
	Lowest quintile of IRSAD	5 (4.4)	15 (10.3)	0.08
Pre-existing condition		N (% total)	N (% total)	p-value
	Preterm (<37 weeks)	25 (22.1)	12 (8.3)	0.002
	Neurological/ syndrome	17 (15)	17 (11.7)	0.44
	Significant Cardiac	5 (4.4)	2 (1.4)	0.14
	Immunocompromised	1 (0.9)	-	
Clinical findings		N (% total)	N (% total)	p-value
	Fever	101 (89.4)	136 (93.8)	0.2
	Subcostal recessions	66 (58.4)	77 (53.1)	0.4
	Wheeze	39 (34.5)	58 (40)	0.37
Respiratory support at admission		N (% total)	N (% total)	p-value
	Any respiratory support	54 (47.8)	57 (39.3)	0.17
	Low flow oxygen	35 (31)	46 (31.7)	0.9
	Pressure support	15 (13.3)	10 (6.9)	0.09
	Mechanical	4 (3.5)	1 (0.7)	0.11

Peak Respiratory Support	N (% total)	N (% total)	p-value
Any respiratory support	69 (61.1)	99 (68.3)	0.23
Low flow oxygen	42 (37.2)	83 (57.2)	0.002
Pressure support	23 (20.4)	15 (10.3)	0.02
Mechanical	4 (3.5)	1 (0.7)	0.11
ICU admission	8 (7.1)	3 (2.1)	0.05
Antibiotics	N (% total)	N (% total)	p-value
During Admission	86 (76.1)	92 (63.4)	0.03
Indication: Bacterial ALRI	64 (56.6)	78 (53.8)	0.65
On discharge	65 (57.5)	75 (51.7)	0.35
Clinical Intervention	N (% total)	N (% total)	p-value
Blood test	91 (80.5)	91 (62.8)	0.002
CXR	86 (76.1)	103 (71)	0.36
Length of Stay	Days (IQR)	Days (IQR)	p-value
ALL	2 (1.5- 4.1)	1.8 (1-2.9)	0.02
Excluding <37wk	1.9 (1.4-3.5)	1.81 (1- 2.8)	0.17
Re-admitted 7 days	5 (4.4)	2 (1.4)	0.14

Supplementary Table 3. Comparison of demographic and clinical features of RSV OALRI admissions in 2019 and 2020

CI, confidence interval; CXR, chest X-ray; ICU, intensive care unit; IQR, interquartile range; N, number; OALRI, other acute lower respiratory tract infection; RSV, respiratory syncytial virus. IRSAD, Index of Relative Socio-economic Advantage and Disadvantage

